The test, developed by Researchers at the Institute for Global Food Security at Queen’s University Belfast, can detect proteases, enzyme markers that are responsible for the progression of many diseases.
News & Features
Focus on strategies that treat patients before they go on opioids, says a medical doctor and medtech innovator speaking in an upcoming MD&M West 2019 panel discussion.
Israel-based Itamar Medical plans to use the net proceeds to accelerate its revenue growth through direct expansion of its sales and marketing initiatives.
FDA cannot accept new 2019 user fees during the government shutdown, which means the agency cannot accept new medical product applications.
The collaboration will use the Apple Watch to measure the outcomes of J&J’s heart health engagement program.
The acquisition comes hot on the heels of Boston Scientific making a significant acquisition into the mitral valve space.
The Irvine, CA-based company is slated to pay out $180 million to Boston Scientific in a move that would end both firms’ outstanding TAVR lawsuits and injunctions.
Abbott says its Amplatzer Piccolo Occluder is the first device approved for use in the tiniest babies (weighing as little as two pounds) to treat patent ductus arteriosus, a common congenital defect.
The Palo Alto, CA-based company will collaborate with Magic Leap, a specialist in augmented reality and spatial computer technology to bring its technology to an AR platform.
ARGONet is an AI solution developed by researchers from the Computational Health Informatics Program at Boston Children’s Hospital, and results evaluating the method's effectiveness were published in Nature Communications.
Awaiting congressional approval, the United States-Mexico-Canada Agreement could reduce duplicative regulations while increasing intellectual property protections, among other changes.
An artificial intelligence solution that can identify precancerous changes in a woman’s cervix, comes on the heels of a Mayo Clinic Study that shows the percentage of women who are screened for cervical cancer could be far lower than national data suggests.
FDA has granted AWAK Technologies a breakthrough device designation for a wearable and ultra-portable peritoneal dialysis device.